Document is current
Any future updates will be listed below
-
Authors
Gjermeni, Diona
Anfang, Viktoria
Szabó, Sofia
Vetter, Hannah
Venhoff, Ana C.
Leggewie, Stefan
Hesselbarth, David
Trenk, Dietmar
Buechsel, Martin
Westermann, Dirk
Olivier, Christoph B.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Received: 26 June 2023
Accepted: 16 April 2024
First Online: 21 May 2024
Declarations
:
: The protocol was approved by the ethics committee of the Albert-Ludwigs-University Freiburg, Germany (registry number 194/20). The study was registered at the German Clinical Trials Register (DRKS00021212). All participants in the study have given written consent to participate in the study and to publish the data.
: All patients participating in the study have given written consent to participate in the study and to publish the results. They received all necessary written information regarding the conduct of the study including the right of withdraw from the study. The consent and information letter were approved by ethics committee of Alberts-Ludwigs-University Freiburg, Germany (registry number 194/20).
: CBO received research support from Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, University of Freiburg, Else Kröner-Fresenius Stiftung, and Haemonetics; Honoraria: Bayer Vital GmbH, BMS, Böhringer Ingelheim, Daiichi Sankyo, Ferrer, Idorsia, and Janssen. DT received research funding from the German Cardiac Foundation and speakers fee and honoraria for advisory board activity from AstraZeneca, ATRIVA Therapeutics, Bayer, Daiichi Sankyo, DP-Medsystems, Ferrer and Novartis.
